What is AZN's current stock price?

As of now, AZN is trading at $90.61, with a daily change of +0.83%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN

Astrazeneca

$90.61

+$0.75 | +0.83%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$94.02

MKT CAP

$283.47B

52W Low

$61.24

VOL

$5.56M

P/E Ratio

30.1

AVG VOL

$5.63M

RSI

54.86

TREND

Uptrend

AZN Stock IQ

Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Target Price

Login to display

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

AZN Price Performance

$91 (-0.43%)

$73.53 (+23.23%)

$76.59 (+18.31%)

$66.25 (+36.77%)

1year

6month

3month

1month

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Analysts Opinion

AZN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

86%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

90%

5%

Positive

Negative

18 out of 20
events present

1 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$90.61

Resistance
Price

$86.19

Current Price Range

$93.32

Show methods +

Linked to AZN

IQ

Close Price

Change

PFE

3.94

25.04

-0.08%

MRK

4.03

100.69

+1.49%

NVS

4.27

135.27

+0.18%

SNY

4.02

47.99

-0.31%

HCM

4.00

13.35

+0.68%

AZN Latest Analysis +

AstraZeneca Gets FDA Nod For Breast Cancer Drug EU Clearance For Lupus Pen. The United States Food (FDA) on Monday approved ) and Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for patients with a certain type of breast cancer.The covers the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.The approval follows and Breakthrough Therapy Designation by the FDA and is based on the results of the DESTINY-Breast09 Phase 3 trial.In

Tue Dec 16, 2025

$91.35 | -0.23%

Activity

Heres Why Astrazeneca (AZN) is a Strong Growth Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Tue Dec 16, 2025

$91.35 | -0.23%

Potential

AstraZeneca Announces Approval Of Saphnelo In The EU . (RTTNews) - AstraZeneca PLC (AZN AZN.L ZEG.DE AZN.ST) said its Saphnelo - anifrolumab - has been approved in the European Union for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus on top of standard therapy. The approva

Tue Dec 16, 2025

$91.35 | -0.23%

Activity

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts. Astrazeneca (AZN) closed the most recent trading day at $91.56 moving 1.93% from the previous trading session.

Mon Dec 15, 2025

$91.56 | +1.93%

Momentum

Global Molecular Cytogenetics Market Set to Reach USD 1.43 Billion by 2030 | MarketsandMarkets™. Delray Beach FL Dec. 11 2025 (GLOBE NEWSWIRE) -- Emerging markets breakthrough technologies and strategic M&.A reshape competitive landscapeThe global is projected to reach USD 1.43 billion by 2030 from USD 1.02 billion in 2025 at a CAGR of 7.1% from 2025 to 2030. The surge is attributed to rapidly increasing global cancer rates growing genetic disorder prevalence and the expanding adoption of ad

Thu Dec 11, 2025

$90.29 | -1.33%

Activity

Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In?.

Wed Dec 10, 2025

$91.51 | +1.88%

Activity

Potential

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma.

Wed Dec 10, 2025

$91.51 | +1.88%

Potential

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain | DelveInsight. Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain |. DelveInsightAcute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults the global rise in aging populations i

Thu Dec 4, 2025

$90.03 | -0.90%

Activity

AstraZeneca GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report. The United Kingdom government is bringing together senior pharmaceutical executives to help chart a new direction for the country'.s .Whitehall officials will invite reps from ) and ) to join the panel.Sky News that the group will analyze successors to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG).VPAG is set to expire in roughly three years.The initiative reflects rising tensions. Pharma

Wed Dec 3, 2025

$90.85 | +0.75%

Activity

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wed Dec 3, 2025

$90.85 | +0.75%

Momentum

FAQ About AZN Stock Insights

What is AZN current stock price?

What are AZN stock strengths?

What is AZN Risk Level?

What is AZN market cap and volume?

What is AZN current Stock IQ?

Should I buy AZN stock right now?

Is AZN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AZN?

What does a 'Strong Sell' rating mean for AZN?

What factors influence AZN's Stock IQ?

Explore our AZN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AZN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AZN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AZN

Astrazeneca

Current Price

$90.61

+$0.75 | +0.83%

52W High

$94.02

MKT CAP

$283.47B

52W Low

$61.24

VOL

$5.56M

P/E Ratio

30.1

AVG VOL

$5.63M

RSI

54.86

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

Linked to AZN

Symbol

IQ

Close

Change

PFE

3.94

25.04

-0.08%

MRK

4.03

100.69

+1.49%

NVS

4.27

135.27

+0.18%

SNY

4.02

47.99

-0.31%

HCM

4.00

13.35

+0.68%

AZN Price Performance

$91 (-0.43%)

$73.53 (+23.23%)

$76.59 (+18.31%)

$66.25 (+36.77%)

1year

6month

3month

1month

AZN Analysts Opinion

AZN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

90%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

86%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

90%

5%

Positive

Negative

18 out of 20
events present

1 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$90.61

Resistance
Price

$86.19

Current Price Range

$93.32

Show methods +

AZN Stock IQ

Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Latest Analysis

AstraZeneca Gets FDA Nod For Breast Cancer Drug EU Clearance For Lupus Pen. The United States Food (FDA) on Monday approved ) and Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for patients with a certain type of breast cancer.The covers the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.The approval follows and Breakthrough Therapy Designation by the FDA and is based on the results of the DESTINY-Breast09 Phase 3 trial.In

Tue Dec 16, 2025

$91.35 | -0.23%

Activity

Heres Why Astrazeneca (AZN) is a Strong Growth Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Tue Dec 16, 2025

$91.35 | -0.23%

Potential

AstraZeneca Announces Approval Of Saphnelo In The EU . (RTTNews) - AstraZeneca PLC (AZN AZN.L ZEG.DE AZN.ST) said its Saphnelo - anifrolumab - has been approved in the European Union for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus on top of standard therapy. The approva

Tue Dec 16, 2025

$91.35 | -0.23%

Activity

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts. Astrazeneca (AZN) closed the most recent trading day at $91.56 moving 1.93% from the previous trading session.

Mon Dec 15, 2025

$91.56 | +1.93%

Momentum

Global Molecular Cytogenetics Market Set to Reach USD 1.43 Billion by 2030 | MarketsandMarkets™. Delray Beach FL Dec. 11 2025 (GLOBE NEWSWIRE) -- Emerging markets breakthrough technologies and strategic M&.A reshape competitive landscapeThe global is projected to reach USD 1.43 billion by 2030 from USD 1.02 billion in 2025 at a CAGR of 7.1% from 2025 to 2030. The surge is attributed to rapidly increasing global cancer rates growing genetic disorder prevalence and the expanding adoption of ad

Thu Dec 11, 2025

$90.29 | -1.33%

Activity

Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In?.

Wed Dec 10, 2025

$91.51 | +1.88%

Activity

Potential

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma.

Wed Dec 10, 2025

$91.51 | +1.88%

Potential

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain | DelveInsight. Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100 Key Pharma Companies Actively Working in the Domain |. DelveInsightAcute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults the global rise in aging populations i

Thu Dec 4, 2025

$90.03 | -0.90%

Activity

AstraZeneca GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report. The United Kingdom government is bringing together senior pharmaceutical executives to help chart a new direction for the country'.s .Whitehall officials will invite reps from ) and ) to join the panel.Sky News that the group will analyze successors to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG).VPAG is set to expire in roughly three years.The initiative reflects rising tensions. Pharma

Wed Dec 3, 2025

$90.85 | +0.75%

Activity

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wed Dec 3, 2025

$90.85 | +0.75%

Momentum

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AZN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AZN Stock trends

AZN Stock performance

AZN Stock analysis

AZN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN Stock IQ

AZN Target Price

AZN Risk Level

AZN Analysts Opinion

AZN Street Sentiment

AZN Performance Sentiment

Technical Price Levels

Explore our AZN Stock insights

Receive our AZN Daily Alerts

AZN Street Sentiment

AZN Risk Level

Technical Price Levels

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

Receive our AZN Daily Alerts

AZN Runner Alarm